Skip to content
Screener

Regenxbio RGNX Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$108.0MBeat by $10.4M
EPS$0.43Beat by $0.35
Revenue estimate$97.6M
EPS estimate$0.08
“Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE® trial met its primary endpoint, we dosed the first participant in the NAAVIGATE study in diabetic retinopathy, and the FDA reaffirmed the path forward for RGX-121. With this progress and our strong cash runway, we are well positioned to deliver against multiple near-term, high-value catalysts, including the initiation of the RGX-202 BLA this quarter and wet AMD pivotal data in the coming months, as we advance potentially transformative gene therapies to patients.”
Curran Simpson

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$15.9M
EPS estimate-$1.21

Financials

Q2 2026

Income statement

See full
Revenue$108.0M+406%
Operating income$29.3M+146%
Net income$22.7M+132%
EPS (diluted)$0.43+131%

Balance sheet

See full
Cash & equivalents$36.5M-54.1%
Total debt$69.0M-11.3%
Total equity$71.8M-66.4%
Total assets$386.6M-33.5%

Cash flow

See full
Operating cash flow-$62.2M-26.1%
CapEx$760.0K+94.4%
Free cash flow-$63.0M-26.7%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$524.47M+15.5%
Enterprise value$556.94M+23.1%
P/S3×+0.1×

Profitability

See full
Operating margin-94.1%-9.3pp
Net margin-112.6%-0.1pp
FCF margin-143.1%-456pp

Returns & leverage

See full
Return on equity-137.6%-817pp
Debt / equity1×+0.6×
Current ratio2.9×-0.3×

Segments

By product

See full
Abb Vie Development Milestone$100.0M—
Zolgensma And Itvisma Royalties$3.8M-79.2%
Nippon Shinyaku Services$3.7M+36.8%
Other Service Revenue$458.0K+163%

FAQ

When did Regenxbio report Q2 2026 earnings?
Regenxbio (RGNX) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Regenxbio's Q2 2026 revenue and EPS?
Regenxbio reported revenue of $108.0M and eps of $0.43 for Q2 2026.
Did Regenxbio beat estimates in Q2 2026?
Revenue beat the consensus estimate of $97.6M by $10.4M. EPS beat the consensus estimate of $0.08 by $0.35.
How did Regenxbio's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 405.7% from $21.4M a year earlier.
Where can I find Regenxbio's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-336716) and the 10-Q periodic report (0001193125-26-336725) directly on SEC EDGAR. The filing index links above go to sec.gov.